-- Data Presented at American Society of Hematology (ASH) Annual Meeting -- With a median follow-up of 12.3 months (range: 7.0 to 32.3 months) at the time of data cutoff, 57 percent of patients ...
– At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-Term Response in Adult Patients with Relapsed/Refractory (R/R) Mantle Cell ...
– ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients – – Real-World Evidence Analysis Shows High ...
Kite, a Gilead Company, today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus™ in adult patients with relapsed or refractory mantle cell lymphoma. At a median follow-up of 17.5 ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts After a median follow-up of ...
NEW ANALYSES PRESENTED AT ASH 2023 SUPPORT THE POTENTIAL LONG-TERM RESPONSE AND SAFETY OF KITE’S TECARTUS ® (BREXUCABTAGENE AUTOLEUCEL) IN PATIENTS WITH AGGRESSIVE BLOOD CANCERS – At Almost Four Years ...
ORLANDO, Fla.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-2, a global, multicenter, single-arm, open-label Phase 2 study of KTE-X19, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback